Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01896271 · ClinicalTrials.gov registry record · Phase 2
High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT01896271 is a Phase 2 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 30 participants.
The verdict
NCT01896271, a Phase 2 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
In this i-SABR (immunotherapy + Stereotactic Ablative Body Radiation) trial, the stereotactic radiation to multiple metastatic sites is delivered not only to eradicate sites of bulky progressive disease, but also to provide antigen presentation and immune stimulation which is expected to act synergistically when immediately followed by the non-specific immune stimulation provided by treatment with HD IL-2 and thereby increase the response rate and complete response for metastatic clear cell renal cell cancer patients. Both HD IL-2 and SABR are FDA approved therapeutic cancer treatment
Interventions
- DRUG IL-2
- RADIATION Stereotactic Ablative Body Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-10-02 |
| Est. Completion | 2021-04-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01896271
The ClinicalTrials.gov registry entry for NCT01896271 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IL-2 is the first listed.
NCT01896271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01896271 about?
NCT01896271 is a clinical study titled "High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer". In this i-SABR (immunotherapy + Stereotactic Ablative Body Radiation) trial, the stereotactic radiation to multiple metastatic sites is delivered not only to eradicate sites of bulky progressive disease, but also to provide antigen presentation and immune stimulation which is expected to act synergi...
What is the current status of trial NCT01896271?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2013-10-02. Estimated completion is 2021-04-20.
What interventions are being tested in trial NCT01896271?
The interventions under investigation include: IL-2 (DRUG), Stereotactic Ablative Body Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT01896271?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.